Oncothyreon Inc (CASC) Rating Reiterated by Cantor Fitzgerald

Oncothyreon Inc (CASC) Rating Reiterated by Cantor Fitzgerald


's stock had its "hold" rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $2.00 price objective on the biopharmaceutical company's stock.



from Biotech News